(JREE) JPMorgan s (Ireland) ICAV - Overview
Etf: Europe, Stocks, Large-Cap, Developed, Diversified
| Risk 5d forecast | |
|---|---|
| Volatility | 11.3% |
| Relative Tail Risk | 1.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.78 |
| Alpha | 9.78 |
| Character TTM | |
|---|---|
| Beta | 0.152 |
| Beta Downside | 0.306 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.63% |
| CAGR/Max DD | 0.77 |
Description: JREE JPMorgan s (Ireland) ICAV January 18, 2026
The Europe Research Enhanced Index Equity UCITS ETF (ticker JREE) tracks the Morningstar DM Eur TME NR EUR index and is domiciled in Germany. It is classified as a Europe Large-Cap Blend Equity ETF, offering investors exposure to a diversified basket of Eurozone large-cap stocks with a blend of growth and value characteristics.
As of the latest data (Q4 2025), JREE carries an expense ratio of 0.15% and manages roughly €2.8 billion in assets, placing it among the higher-capacity ETFs in the region. Its top ten holdings are heavily weighted toward the financials, consumer discretionary, and industrials sectors-reflecting the current Eurozone economic recovery driven by improving credit conditions, resilient consumer spending, and a modest rebound in manufacturing output. The fund’s performance over the past 12 months has outperformed the MSCI Europe Large-Cap Index by about 120 bps, partly due to its enhanced weighting methodology that tilts toward higher-quality earnings growth.
For a deeper dive into the fund’s risk-adjusted returns and sector attribution, you might find ValueRay’s analytical tools useful-just a quick look could help you validate whether JREE fits your portfolio objectives.
What is the price of JREE shares?
Over the past week, the price has changed by +1.14%, over one month by +2.44%, over three months by +9.49% and over the past year by +15.18%.
Is JREE a buy, sell or hold?
What are the forecasts/targets for the JREE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 58.8 | 12% |
JREE Fundamental Data Overview February 05, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.22b EUR (1.22b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.22b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.22b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.48% (E(1.22b)/V(1.22b) * Re(6.48%) + (debt-free company))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)